WebThe recommended niraparib dose for first-line maintenance treatment of advanced ovarian cancer is based on body weight or platelet count. For patients weighing less than 77 kg … WebOct 25, 2024 · PARP inhibitor maintenance therapy is standard of care for newly diagnosed patients with ovarian cancer and patients with platinum-sensitive relapse who have not received previous PARP inhibitor therapy. The majority of patients, however, will ultimately experience disease progression.
Senaparib Achieves Notable Survival Benefit in Advanced Ovarian Cancer
WebMay 8, 2024 · PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as a first-line maintenance therapy for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy. The FDA also approved a test that helps to identify women who will benefit from this combination therapy. WebMar 30, 2024 · In women with newly diagnosed ovarian cancer, bevacizumab and poly (ADP-ribose) polymerase inhibitors (PARPi) exhibit improved progression-free survival (PFS) when administered concurrent with chemotherapy and/or maintenance therapy, but no study has directly compared their effects. nto meaning in business
Olaparib: A Review as First-Line Maintenance Therapy in ... - PubMed
WebFeb 22, 2024 · Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treat Rev (2024) 80 :101909. 10.1016/j.ctrv.2024.101909 [ PubMed ] [ CrossRef ] [ Google Scholar ] WebOlaparib Maintenance Therapy for Ovarian Cancer When used as maintenance therapy, the PARP inhibitor olaparib provided a significant progression-free survival benefit in … WebSep 14, 2024 · Another PARP inhibitor, niraparib (Zejula™), was approved earlier this year as maintenance therapy for patients with recurrent ovarian cancer whether or not they … nt-on-access scanner